Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome

Clinical Research in Cardiology

Volumn 106, Issue 5, 2017, Pages 359-368

  Farmakis, Dimitrios ^a   Simitsis, Panagiotis ^a   Bistola, Vasiliki ^a   Triposkiadis, Filippos ^b   Ikonomidis, Ignatios ^a   Katsanos, Spyridon ^a   Bakosis, George ^a   Hatziagelaki, Erifili ^a   Lekakis, John ^a   Mebazaa, Alexandre ^c   Parissis, John ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Acute heart failure; Hospitalized heart failure patients; Intermediate left ventricular ejection fraction; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; EPINEPHRINE; LEVOSIMENDAN; NORADRENALIN; VASODILATOR AGENT;

ACUTE HEART FAILURE; AGED; ANURIA; ARTICLE; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC KIDNEY FAILURE; DYSLIPIDEMIA; DYSPNEA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL MANAGEMENT; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OLIGURIA; OXYGEN SATURATION; SYSTOLIC BLOOD PRESSURE; ACUTE DISEASE; AUSTRALIA; CLINICAL TRIAL; COMORBIDITY; EPIDEMIOLOGY; EUROPE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HOSPITAL MORTALITY; HOSPITALIZATION; INCIDENCE; MULTICENTER STUDY; PREVENTION AND CONTROL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH AND CENTRAL AMERICA; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; AUSTRALIA; COMORBIDITY; EUROPE; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INCIDENCE; LATIN AMERICA; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85006753279     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-016-1063-0     Document Type: Article

References (28)

1. Yancy CW, Lopatin M, Stevenson LW, De MT, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47:76–84
2. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50:768–777
3. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J, Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology (2003) The EuroHeart failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24:442–463
4. Farmakis D, Parissis J, Filippatos G (2015) Acute heart failure: epidemiology, classification, and pathophysiology. In: Tubaro M, Vranckx P, Price S, Vrints C (eds) The ESC textbook of intensive and acute cardiac care, 2nd edn. Oxford University Press, Oxford, UK
5. Farmakis D, Parissis J, Lekakis J, Filippatos G (2015) Acute heart failure: epidemiology, risk factors, and prevention. Rev Esp Cardiol 68:245–248
6. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, Tschöpe C, Metra M, Hummel SL, Edelmann F, Ambrosio G, Stewart Coats AJ, Filippatos GS, Gheorghiade M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM (2014) New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 35:2797–2815
7. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781
8. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338–2345
9. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467
10. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S (2014) McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392
11. Ohlmeier C, Mikolajczyk R, Frick J, Prütz F, Haverkamp W, Garbe E (2015) Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons. Clin Res Cardiol 104:688–696
12. Vaduganathan M, Michel A, Hall K, Mulligan C, Nodari S, Shah SJ, Senni M, Triggiani M, Butler J, Gheorghiade M (2016) Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail 18:54–65
13. Toma M, Ezekowitz JA, Bakal JA, O’Connor CM, Hernandez AF, Sardar MR, Zolty R, Massie BM, Swedberg K, Armstrong PW, Starling RC (2014) The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. Eur J Heart Fail 16:334–341
14. Lam CS, Solomon SD (2014) The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 16:1049–1055
15. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA (2005) Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112:3738–3744
16. Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA (2002) Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 137:631–639
17. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975
18. Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A (2011) Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 37:619–626
19. Parissis JT, Ikonomidis I, Rafouli-Stergiou P, Mebazaa A, Delgado J, Farmakis D, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F (2011) Clinical characteristics and predictors of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction. Am J Cardiol 107:79–84
20. Parissis J, Farmakis D, Kadoglou N, Ikonomidis I, Fountoulaki E, Hatziagelaki E, Deftereos S, Follath F, Mebazaa A, Lekakis J, Filippatos G (2016) Body mass index in acute heart failure: association with clinical profile, therapeutic management and in-hospital outcome. Eur J Heart Fail 18:298–305
21. Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT, van der Harst P, Rienstra M, van Gelder IC, van Veldhuisen DJ, van Gilst WH, van der Meer P (2015) Sex differences in new-onset heart failure. Clin Res Cardiol 104:342–350
22. Ogah OS, Davison BA, Sliwa K, Mayosi BM, Damasceno A, Sani MU, Mondo C, Dzudie A, Ojji DB, Kouam C, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Cotter G (2015) Gender differences in clinical characteristics and outcome of acute heart failure in sub-Saharan Africa: results of the THESUS-HF study. Clin Res Cardiol 104:481–490
23. Parissis JT, Andreoli C, Kadoglou N, Ikonomidis I, Farmakis D, Dimopoulou I, Iliodromitis E, Anastasiou-Nana M, Lainscak M, Ambrosio G, Mebazaa A, Filippatos G, Follath F (2014) Differences in clinical characteristics, management and short-term outcome between acute heart failure patients with chronic obstructive pulmonary disease and those without this co-morbidity. Clin Res Cardiol 103:733–741
24. Ishihara S, Gayat E, Sato N, Arrigo M, Laribi S, Legrand M, Placido R, Manivet P, Cohen-Solal A, Abraham WT, Jessup M, Mebazaa A (2016) Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure. Clin Res Cardiol 105:971–980
25. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) (2012) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33:1750–1757
26. He KL, Burkhoff D, Leng WX, Liang ZR, Fan L, Wang J, Maurer MS (2009) Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40–55% versus <40%. Am J Cardiol 103:845–851
27. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, TOPCAT Investigators (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:455–462
28. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM (2012) Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 5:720–726